==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1134 which contains 1 entries.


Entry 1
(1) Primary information
ID1621
ThPP IDTh1134
Therapeutic Peptide/Protein NameAsparaginase erwinia chrysanthemi
SequenceADKLPNIVILATGGTIAGSAATGTQTTGYKAGALGVDTLINAVPEVKKLA view full sequnce in fasta
Functional ClassificationIc
Molecular Weight140000
Chemical FormulaC1546H2510N432O476S9
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeElimination half life- 16 hrs
DescriptionErwinaze (asparaginase from Erwiniachryanthemi) is an asparaginase specific enzyme derived from Erwiniachrysanthemi. L-asparaginase is a homo-tetramer with each subnuit having a molecular weight of about 35 kDa. It is an antineoplastic agent and was FDA approved in November 19, 2011.
Indication/DiseaseAsparaginase Erwinia chryanthemi is for the treatment of patients with acute lymphoblastic leukemia (ALL) that have developed a hypersensitivity to Escherichia coli-derivied asparaginase. It is a component of a multi-agent chemotherpeutic regimen for the treatment of the aforementioned disease and is considered second- or third- line treatment in European and American protocols.
PharmacodynamicsN.A.
Mechanism of ActionAsparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resulting in a reduction in circulating levels of asparagine in the plasma. The mechanism of action of Erwinaze is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting in cytotoxicity specific for leukemic cells that depend on an exogenous source of the amino acid asparagine for their protein metabolism and survival.
ToxicityBecause Erwinaze is injected intramuscularly, there is a higher chance of experiencing major skin reactions. Although the perceived benefit of Erwinia chryanthemi-derivied asparaginase is a lower incidence of hypersensitivity, there is still a chance that one may experience symptoms such as, but not limited to, anaphylaxis, pain, edema. Pancreatitis may also occur during the first few weeks of treatment with asparaginase.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesEnzymes
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameErwinaze
CompanyEUSA Pharma
Brand DiscriptionERWINAZE (asparaginase Erwinia chrysanthemi) contains an asparagine specific enzyme derived from Erwinia chrysanthemi. L-asparaginase is a tetrameric enzyme consisting of four identical subunits, each having a molecular weight of about 35 kDa. The activity of ERWINAZE is expressed in terms of International Units.
Prescribed foracute lymphoblastic leukemia
Chemical NameN.A.
FormulationEach vial contains 10,000 International Units of asparaginase Erwinia chrysanthemi, and the following inactive ingredients: glucose monohydrate (5.0 mg), sodium chloride (0.5 mg).
Physcial AppearanceERWINAZE is supplied as a Sterile, lyophilized, white powder in vials.
Route of AdministrationIntramuscular
Recommended Dosage25,000 International Units/m²
ContraindicationHypersensitivity reactions to ERWINAZE, including anaphylaxis., pancreatitis with prior L-asparaginase therapy, thrombosis with prior L-asparaginase therapy, hemorrhagic events with prior L-asparaginase therapy.
Side EffectsHypersensitivity reactions, Pancreatitis, Glucose intolerance, Thrombosis and hemorrhage
Useful Linkhttp://www.rxlist.com/erwinaze-drug.htm http://erwinaze.com/ http://www.drugs.com/erwinaze.html
PubMed ID25098829, 24436152, 23794007, 22499236
3-D StructureTh1134 (View) or (Download)